Causes of Deranged PT/INR
A deranged PT/INR is primarily caused by vitamin K antagonist (warfarin) therapy, liver disease affecting synthesis of clotting factors (I, II, V, VII, X), consumption of coagulation factors (such as in DIC), vitamin K deficiency, or drug interactions—but critically, the INR was designed and validated only for monitoring warfarin therapy and should not be interpreted the same way in other clinical contexts. 1, 2, 3
Primary Causes in Warfarin-Treated Patients
For patients on vitamin K antagonists, the following factors increase PT/INR: 3
- Drug interactions (numerous medications through enzyme inhibition, reduced protein binding, or synergistic effects on hemostasis) 3
- Dietary changes (reduced vitamin K intake, changes in green leafy vegetables) 3
- Acute illness (fever, diarrhea, hyperthyroidism, congestive heart failure) 3
- Hepatic dysfunction (infectious hepatitis, steatorrhea) 3
- Poor nutritional state and vitamin K deficiency 3
- Genetic variations in CYP2C9 and VKORC1 enzymes affecting warfarin metabolism 4, 3
Factors that decrease PT/INR in warfarin patients include: 3
- Enzyme-inducing medications (rifampin, carbamazepine, phenobarbital, phenytoin) 3
- Vitamin K intake (dietary increases or supplementation) 3
- Hypothyroidism and hyperlipidemia 3
- Warfarin underdosing or non-adherence 3
Causes in Non-Warfarin Patients
In patients NOT on warfarin, an elevated PT/INR indicates: 5, 2
- Liver disease with impaired synthesis of procoagulant factors (I, II, V, VII, X), though this does NOT measure deficient anticoagulant factors like protein C 5
- Vitamin K deficiency from malabsorption, malnutrition, or prolonged antibiotic use 2, 3
- Consumptive coagulopathy (DIC) depleting clotting factors 2
- Lupus anticoagulant (though this typically causes only slight PT prolongation) 4, 2
Critical Caveat for Liver Disease
The INR in cirrhosis is fundamentally unreliable and should NOT be interpreted as indicating bleeding risk. 5 The test measures procoagulant factors but ignores the simultaneous reduction in anticoagulant factors (especially protein C), creating a misleading picture. 5 Additionally, INR values vary significantly between hospitals depending on which thromboplastin reagent is used, as the test is "normalized" against warfarin-treated patients, not liver disease patients. 5, 6
Technical and Laboratory Factors
PT/INR results can be artificially deranged by: 4, 7, 8
- Thromboplastin reagent variability (different ISI values between laboratories and instruments) 4, 7
- Incorrect citrate concentration in collection tubes (3.8% citrate yields higher INRs than 3.2%) 4
- Underfilled collection tubes (excess citrate spuriously prolongs PT) 4
- Automated clot detection methods affecting accuracy compared to manual methods 4
- Incorrect mean normal PT determination (should use geometric mean from 20 healthy individuals, not laboratory control PT) 4
Clinical Context Matters
The therapeutic INR range of 2.0-3.0 applies ONLY to patients on vitamin K antagonists for conditions like atrial fibrillation. 9, 4 An INR below 2.0 in warfarin patients doubles stroke risk, while INRs above 3.0 increase bleeding risk. 9 However, there is no high-quality evidence supporting treatment of INRs below 2.0 in patients NOT receiving warfarin therapy. 1
Common Pitfall to Avoid
Never use PT/INR as a general screening test for coagulopathy or to predict procedural bleeding risk in non-warfarin patients. 1, 10 The test lacks validity for these purposes and leads to unnecessary plasma transfusions that provide no clinical benefit, increase costs, and cause harm (particularly worsening portal hypertension in cirrhosis). 1, 5
Specific High-Risk Scenarios
In patients with INR >9 on warfarin: 11
- Outpatients have 11% bleeding risk with no mortality 11
- Hospitalized patients have 35% bleeding risk and 17% mortality 11
- Risk factors for bleeding include older age, renal failure, and alcohol use 11
- Withholding warfarin or vitamin K is often ineffective within 24 hours; plasma infusion immediately reduces INR to ~2.4 11
In patients NOT on anticoagulants with INR >9: 11